Many patients with invasive cancer have a compromised immune system. This immune dysfunction does appear to start at the site of the tumor. Locoregional immunotherapy is given to stimulate the immune system in order to kill tumor cells either indirectly via a specific or a non-specific way or directly via cell transfer therapy. Advantages to give this immunotherapy locoregionally in stead of systemically are a higher concentration of the immunomodulator at the site of the tumor, to attract or activate effector cells, and diminished toxicity. In this review we have summarised the clinical studies using loco-regional immunotherapy in patients with cancer. Only phase I and II studies were performed. Clinical responses were seen. No single locoregional treatment has become a standard therapy. Relatively few investigations were performed to estimate the influence on the locally effector mechanisms or immune dysfunction. In future clinical trials it is essential to get a better insight in these mechanisms.
Introduction

Objectives of this review
In this review clinical studies in which patients were exclusively treated with locoregional immunotherapy are summarised.
Although locoregional immunotherapy originates from the 19th century only the most recent studies are discussed. For example the early studies with intralesional BCG or BCG cell wall products in melanoma or head and neck carcinoma are not considered.
Only trials in patients with invasive tumors are described. Patients with basaliomas, papilloma of the trachea and superficial bladder cancer are therefore not mentioned.
Studies in which the effector mechanism was immune-related are reviewed. Therefore, trials with radioimmunotherapy and gene-therapy with a vector that not primarily effects the immune system are excluded. For the same reason, the trials with loco-regional perfusion in which cytokines facilitate the retention of cytostatic agents by an increased vascular permeability at the tumor site [1, 2] are excluded.
The combination of local and systemic therapy only is discussed when the approach is rationally designed and executed, i.e., combination after the availability of sufficient data on the efficacy of each modality.
Locoregional immunotherapy
Immunotherapy can be broadly grouped into three major categories: 1) specific, 2) non-specific, 3) adoptive cell transfer. Therapy is considered specific if it enhances a certain aspect of the specific immune response to the tumor in question, i.e.,T-cell or B-cell (with monoclonal antibodies (Mab) or antibody-dependent cell-mediated cytotoxicity (ADCQ). A more general, non-specific activation of the immune system is when NK-cells, T-LAK cells, macrophages or granulocytes are activated. Adoptive cell transfer therapy is an immunotherapy with mostly autologous immune cells, that have been activated and expanded in vitro, for example Lymphokine activated killer (LAK) cells, Tumor infiltrating lymphocytes (TILs), or dendritic cells. IL-2 gives stimulation both in a specific and non-specific way. The interferons stimulate mostly in a non-specific way, but have also a direct anti-proliferative effect on tumor cells.
In many patients with cancer the immune system is compromised, even early in the course of the disease. This impaired immune function is different from the generalised imtnunosuppression seen in patients receiving high doses corticosteroids or chemotherapy. This immune dysfunction, with both specific and non-specific changes, does appear to start at the site of the tumor and eventually becomes more generalised [3] . The first sign of immune dysfunction is the diminished or absence of tumour recognition. This can be caused by immunological ignorance [4] , down-regulation of tumor-associated antigens (TAAs) or major histocompatibility complex (MHC) molecules [5] or reduction in the proteins of the endoplasmic reticulum (ER), that process and transport antigens over the ER membrane (TAP, i.e., transporterassociated with antigen processing) [6] . Furthermore tumor-infiltrating lymphocytes (TILs) dysfunction is caused by the loss of the T-cell receptor (TCR) C, chain [7] , inhibition of activation of NF-Kb/?6J [8] or apoptosis by Fas ligand (FasL) expression by tumor cells [9, 10] . The lack of co-stimulatory signals (i.e., CD80 or CD86) might be another important event preventing the adequate response of the immune system [11] .
Factors known to interfere with the immune response areTGF-P [12] , prostaglandins [13] , insulin-like growth factor [14] , shedding of intercellular adhesion molecule (ICAM) [15] and gangliosides [16] . In many tumors, the cytokine profile is altered with a decrease in the amount of interleukin-2 (IL-2) and interferon-y (IFN-y) and an increase of interleukin-10 (IL-10), which gives rise to less presentation of TAAs and a lower expression of the MHC molecules [17] .
There are several reasons for giving immunotherapy locoregional in stead of systemic. IL-2 is one of the most frequently used and investigated immunomodulators in oncology. In a lot of animal models it is shown that locoregional immune therapy is far more effective than systemic treatment [18] [19] [20] [21] [22] . The concentration of IL-2 at the site of the tumor is very high after local application compared to intravenous (i.v.) infusion or subcutaneous (s.c.) administration. The target cells, specific primed T cells in combination with macrophages, NK cells and granulocytes, are mainly present at the site of the tumor. IL-2 levels at the site of the tumor will therefore be crucial [23] . Another advantage of locoregional administration compared with systemic administration is a lower toxicity. In another animal study measuring the biodistribution of lymphokine-activated killer T cells (T-LAK cells) it was shown that T-LAK cells administrated by different routes, were able to localise into tumor metastases in various organs, but the concentration of the cells were highest after locoregional administration [24] .
The therapeutical effects of locoregionally immunotherapy in human cancer have been studied on a modest scale. Most clinical studies deal with local recurrent or residual disease, or primarily far-advanced disease for which no conventional treatment was available. Access to the tumor was obtained by direct, endoscopic or ultrasound-guided intra-or peri-tumoral injection, perilymphatic injection, i.e., around the tumor-draining lymph nodes, selected intra-arterial infusion, or compartmental administration into localised body cavities such as peritoneum, pleura, lung (by inhalation), or leptomeninges.
Published studies on locoregional immunotherapy will be discussed by tumor site. Only phase I and II studies were performed and there is no phase III study performed yet.
Clinical studies
Head and neck squamous-cell carcinoma (HNSCC)
HNSCC is characterised by locoregional tumor spread near extensive submucosal and nodular lymphatic tissue. The first therapeutical study with locoregional cytokine based immunotherapy was founded on Forni's compelling data in a mouse system with IL-2 [25] . Cortesina et al. [26] treated patients with locoregional recurrent HNSCC with perilymphatically injected low doses IL-2 in order to activate regional lymphocytes. They obtained 3 complete responses (CR) and 3 partial responses (PR) in 10 patients. Subsequent studies using the similar treatment did not equal this high response rate [27] [28] [29] (Table 1 ). Responses were also described with peritumoral and intra-arterial IL-2 administration [30] [31] [32] . Generally, fewer responses were seen in patients with large tumor masses. In patients with a bilateral lymph node dissection no responses were seen, suggesting the necessity of regional lymph nodes to elicit an immune response [26] . The available data do not permit conclusions regarding the optimal dose or route of administration, i.e., perilymphatic or intratumoral. In the three dose-escalation studies objective responses occurred at the lowest IL-2 dose used, at the highest, or both [29, 31, 33] . Systemic toxicity varied from none or mild fever only, to significant at high dose-levels in the dose-escalation studies. Side effects included temporary moderate local swelling and redness, or pain which appeared not to be dose related. Histological examination of treated tumors showed increased lymphocytic infiltration, macrophages, giant cells, and fibrous changes at the tumor site, and degeneration of cancer cells [30, 32, 34] . Also systemic activation of antitumor effector cells (i.e., increase in NK and LAK cell activity and activated T-lymphocytes) was observed [34] . Because polyethylene glycol (PEG)-modified IL-2 showed in several experimental tumors an enhanced efficacy as compared to IL-2, PEG-IL-2 was used in a clinical study [35] . The response rate was low. OK-432 is a pulverised preparation of the low-virulence SU strain of Streptococcus pyogenes of human origin. It is a multi-cytokine inducer with limited efficacy after systemic administration and has great similarity with the initial studies of Coley in 1890 [36] . Surprisingly, Kitahara et al. described 8 responses in 12 patients after peritumoral injections [37] . The main toxicity was fever (Table 1) .
A new approach is gene therapy. Gleich et al. [38] reported a phase I study using a HLA-B7 (MHC class I) gene by direct intratumoral injection in patients with advanced HNSCC (see direct gene transfer to other sites for the mechanism of action). In nine patients four PR were seen. There were no toxic effects of the gene therapy.
Overall, in HNSCC the response rate of the locoregional immunotherapy (mostly IL-2) was low. There is no reason for a phase III study. However, HNSCC is a good model for investigating the locally induced effects of (new) immunotherapy. The gene transfer therapy is very interesting and phase II studies are ongoing.
Central nervous system
Malignant gliomas The brain has been considered an immunological privileged site, functionally protected from normal cancer 28 (26) 108 (98) 41 ( immunosurveillance mechanisms. Pathological studies of malignant gliomas often show only a minimal host inflammatory response [39] . In addition, several systemic deficiencies of immune function have been identified in brain tumor patients and several inhibiting factors (i.e., transforming growth factor-beta (TGF (32) and an inhibitory interleukin-1 like substance) produced by malignant gliomas have been found [40, 41] . In malignant gliomas immunotherapy is given in case of recurrent disease, mostly after total or subtotal resection. In most studies the locoregional immunotherapy was administered in the cavity which was artificially created after resection of the tumor, often through an Ommaya reservoir. In most studies adoptive cell transfer therapy was given.
In recurrent malignant glioma autologous leucocytes or autologous stimulated lymphocytes (ASL) were administered locoregionally [42, 43] . The cells were given either intrathecal or directly injected intratumorally. The response rate was not exactly determined in these patients, although improvement of neurological signs was described [42] (Table 1 ). The efficacy of this treatment was not obvious. There was no toxicity.
Several clinical trials were conducted with adoptive transfer of LAK cells and IL-2 [44] [45] [46] [47] in patients with recurrence of malignant glioma, mostly glioblastoma multiforme ( Table 1 ). The response rate was difficult to determine. In 1 study in which 23 patients were treated with IL-2 and LAK cells 6 patients had a PR [45] . Hayes et al. treated 19 patients after surgery with IL-2 and LAK cells; after finishing the immunotherapy all patients were offered chemotherapy, including responders.
They obtained 1 CR and 2 PR during immunotherapy and one additional CR 14 months after stopping chemotherapy [47] . The median survival was 12 months, which was longer than in a simultaneously treated (with only chemotherapy) patient population with a survival of only 6 months. However, this does not replace a randomised study. Toxicity consisted mainly of neurological symptoms due to temporary cerebral oedema. Significant biologic changes, characterised by a regional eosinophilia, and extensive lymphocytic infiltration assessed by immunohistochemistry, were correlated with a better survival.
Another approach in recurrent malignant glioma is treatment with autologous stimulated lymphocytes with or without LAK cells and IL-2 [48, 49] . Response rates were not exactly given [48] . There were no major side effects. The given survival data are hardly to interpret. Nitta et al. described treatment with LAK cells pre-incubated by bispecific antibody [50] (Table 1 ). The antibody consisted of an anti-CD3 mAb chemically conjugated with an anti-glioma Ab. In 10 treated patients 4 PR were found. In four additional patients a high density area appeared at the site of the surgical resection, what probably was a good sign, because in two of those patients a biopsy from this area showed necrosis of tumor cells. There was no toxicity.
One study used IFN-(3 in 20 patients with no response [51] (Table 1) . The major difficulty with this form of therapy was a problem with the Ommaya reservoir (obstruction or infection).
Summarising, in malignant glioma in most phase II studies no evaluable disease was present. The effect of therapy was evaluated on clinical improvement and survival. Interpretation of these study parameters is impossible in phase II studies. In most studies no investigations were performed to elucidate potential effector mechanisms. The results obtained so far, do not justify a phase III study.
Leptomeningeal metastases
In one study it was shown that intraventricular injection of IL-2 into patients with leptomeningeal carcinomatosis (from adenocarcinoma of the lung or malignant melanoma) induced release of secondary cytokines, soluble IL-2 receptor and neutrophilic leukocytes, sustained presence of lymphocytes, and decrease of malignant cells in the cerebral fluid [52] . There is no place for this treatment in daily practice.
Intrapleural administration
Intrapleural immunotherapy was studied in two categories of patients: first, in patients with pleural mesothelioma and second, in patients with malignant pleural effusion mainly due to lung and breast cancer and sometimes other cancers. In intraperitoneal tumor models it has been shown that intracavitary administration of IL-2 can induce very high numbers of LAK cells in the peritoneal excudate [53] . The interferons have an antiproliferative effect on tumor cells including mesothelioma and IFN-y is a potent activator of macrophage cytotoxicity against tumor cells.
Pleural mesothelioma is an incurable disease. Intensive treatment with surgery, radiation therapy or chemotherapy has no proven effect on survival. In pleural mesothelioma IFN-y or IL-2 was administered locoregionally through a thin catheter or Port-a-cath system. Response rates (measured on a CT scan of the chest and evaluated according to the criteria of the World Health Organisation) were 32%, 47%, 19% and 54%, respectively [54] [55] [56] [57] with a median time to progression of 12 months [56] (Table 1) . Toxicity was mild, except on high dose-levels and consisted of catheter infection, fever and flue-like symptoms [56] . Patients with a low tumor load had a higher response rate [57] . The level of induced TNF-a and LAK cell activity were not predictive for response [56] . In conclusion the used immunotherapy appears to have anti-tumor activity in pleural mesothelioma. Future studies are required to see if this treatment will prolong survival. However, mesothelioma is a very rare disease, which will be a problem for performing a phase III study.
In the palliative treatment of malignant pleural effusions due to carcinomas of lung, breast or other, IL-2, IFN-p* or IFN-a was administered intrapleurally [58] [59] [60] [61] . Response rates (disappearance of fluid effusion) differed between 38% and 82% (Table 1) . In most responders the cytology of the effusion became negative. The response duration ranged between 2 and 10 months [61] . Toxicity was mild. After IL-2 administration induction of LAK cells was only seen in responders [58] . Rosso et al. [60] observed all the responses in patients with an effusion volume < 1000 ml. Surprisingly, an increased ratio of tumor cells to malignant effusionassociated mononuclear cells and the presence of CD8+ T lymphocytes within the malignant effusions were positive correlated with a response after treatment with IFN-a [61] . This form of treatment has never been tested in a randomised study versus the standard approach, i.e., chemical pleurodesis with intrapleural installation of nitrogen mustard, bleomycin, tetracycline or talc. With these drugs responses occurred in 30%-91% of the cases. No clear benefit has been shown by using the locoregionally immunotherapy instead of the standard therapy and there is no place for this treatment in daily practice.
Ovarian carcinoma
In ovarian cancer residual disease after chemotherapy is a great problem, with limited chance of cure. The disease is very often limited to the intraperitoneal space. Residual ovarian cancer or recurrent ascites has been treated with several intraperitoneal (i.p.) immunotherapeutical agents, because in the intraperitoneal space the cytokine or immune cells can be brought in direct contact with tumor cells. Most responses in ovarian cancer are surgically documented.
Corynebacterium parvum i.p. (a bacterial component) induced a rather profound local reaction and its toxicity prevented more widespread testing [62] . Another way of non-specific treatment was the administration of viral oncolysates [63] (Table 1) . Humoral responses to TAAs and viral antigens were observed in patients demonstrating clinical activity.
On the other hand, IFN-a was locally well tolerated but had significant systemic side effects. It has shown activity in ovarian cancer patients with very small volume, i.e., minimal residual disease (MRD, microscopic disease or tumor nodules < 5 mm) after first-line chemotherapy [64, 65] (Table 1) . Survival data were not given. NK cells obtained from the i.p. cavity revealed an increased cytotoxicity in most patients [64] . However, this increased NK lysis did not correlate with the individual tumor response [66] . There has been substantial evidence to suggest synergy between various interferons and cytotoxic agents, i.e., cisplatin [67] . Therefore IFN-a was given in combination with cisplatin in three studies. In two studies the response rate (RR) of the MRD [68] or malignant ascites [69] was approximately 50%, but in the third only 7% [70] . In this last study most patients had extensive cisplatin-resistant carcinomatosis (Table 1) .
Based on two pilot studies [71, 72] with IFN-y i.p., which showed an increased cytotoxicity of tumor-associated macrophages, secondary release of cytokines and a marked increase of MHC class II molecules, a large phase II study was performed [73] . One hundred eight patients with residual disease at second-look laparotomy were treated with IFN-y i.p.. Of 98 assessable patients, 32% achieved a surgically documented response, with a median duration of 20 months ( Table 1 ). The age of the patient and size of residual tumor were significant prognostic factors for the reponse to IFN-y. Adverse events included fever, flu-like syndrome, neutropenia, and liver enzyme disturbances. No significant peritoneal fibrosis was noted. Controlled prospective trials are required to determine the place of IFN-Y 'P-' n ovarian cancer.
IL-2 was given in a number of studies, sometimes together with LAK cells [74, 75] , in another study with tumor infiltrating lymphocytes (TIL) [76] or as single agent [77] (Table 1) . Toxicity of IL-2 i.p. was rather high, with intraperitoneal fibrosis being the greatest problem. Other toxicity included abdominal pain secondary to accumulation of ascites and systemic effects, i.e., fever, nausea and vomiting and diarrhoea [74, 75] . LAK cell activity was increased intraperitoneal and to a lesser degree in the peripheral blood [74] . Edwards et al. [77] compared two schedules of IL-2 i.p.; IL-2 was better tolerated as a weekly infusion as compared with a sevenday infusion. The RR was 26%. In this phase II study a prolonged survival was suggested, but only a randomised trial can address this question. In this study catheter infection was the most important toxicity.
Canevari et al. [78] administered to patients with advanced ovarian carcinoma autologous, ex vivo expanded T lymphocytes re-targeted with bi-specific (bs) Mab OC/TR, combined with soluble OC/TR and low dose IL-2 i.p.. The bs-Mab OC/TR is specific for CD3 on T lymphocytes and for a high affinity folate-binding protein (MOvl8) which is overexpressed by about 90% of ovarian carcinomas [79] . The supposed mechanism of action is probably based on an initial bispecific Mab-retargeted T-cell response directed against folate binding protein-positive cells, which in turn triggers a non-specific inflammatory reaction [78] . They observed only local anti-tumor effects, with a RR of 23% in 26 evaluable patients and disappointingly no systemic antitumor effects. This matched with the observation that the treatment resulted in substantial local immunomodulation but virtually no systemic immunomodulation [80] .
In summarise, it can be stated, that in ovarian cancer, response rates differed between 0 and 53%, with also the occurrence of complete responses. Although the number of treated patients is sometimes high, a phase III study to identify a possible survival advantage has not been performed. Relatively few investigations have been performed for searching to the effector mechanisms. It is not clear if IFN-y is superior to other intraperitoneal immunotherapeutics, for example IFN-a, but the data presented are challenging. Therefore IFN-y might be a candidate for further investigation.
Direct gene transfer to other sites
Direct intratumoral gene transfer or gene therapy offers a novel approach to augment tumor cell immunogenicity while minimising systemic toxicities. The published clinical studies of gene therapy influencing the immune system transferred an HLA-B7 gene, an IL-2 gene or IFN-y gene intratumorally ( Table 1 ). The differences in vectors will not be discussed, because it is beyond the scope of this review.
The expression of MHC class I molecules is often decreased or undetectable in tumors. However, these molecules are necessary for TAA-recognition and activation of CD8+ CTLs. In an animal model [81] it was shown that intratumoral injection of allogeneic MHC genes into murine tumors resulted in induction of CTLs against tumor cells. Nabel et al. [82] published the first clinical results in five patients with malignant melanoma (MM) treated with intratumoral injections of an allogeneic MHC class I gene HLA-B7, in a cationic lipid vector. Since than, six other clinical studies (melanoma, renal cell carcinoma, colon cancer, head and neck cancer (see above) or other cancer) are published [38, [83] [84] [85] [86] [87] ( Table 1 ). In post-treatment biopsies HLA-B7 was demonstrated in the majority of the patients in all studies. However, HLA-B7-reactive cytotoxicT-lymphocytes (CTLs) were only found in the minority of treated patients. The treatment was safe, feasible and associated with minimal toxicity (related to technical aspects of the injection or biopsies). There were responses in head and neck cancer, lung cancer and MM, both in lesions treated with the gene as exceptionally in distant lesions [38, 82, 84, 85, 87] .
The other approach is direct gene transfer of an IL-2 DNA lipid complex in the tumor. In animal models, tumors containing the IL-2 gene showed a significantly more potent stimulus for the immune system in comparison to untransduced cells. Intratumoral injection of the murine equivalent of this IL-2 gene showed complete tumor regression mediated by CD8+ cells [88] . Galanis et al. [89] treated 74 patients with IL-2 DNA lipid complex. There were three PR in RCC or MM and there was regression of the injected tumor in another nine patients. Toxicity was mild and existed mainly of constitutional symptoms. The IL-2 plasmid was detected in post treatment samples of 29 of 46 evaluated patients. Post treatment biopsy specimens showed an increased IL-2 expression and infiltration of CD8+ cells. One other phase I study used an adenovector-mediated gene delivery of IL-2 in subcutaneous localisations of melanoma or breast cancer [90] . Local inflammation was observed at the site of injection in 60% of the patients. The gene expression in tumor biopsies was present in most cases. There were no clinical responses, but six patients had an incomplete local tumor regression at the site of the injection.
One study described the use of an IFN-y retroviral vector administered intratumorally [91] . No toxicity was observed. IFN-y expression was confirmed in only 3 of 10 harvested tumor samples. No responses were seen.
Almost all the above-mentioned trials with gene therapy were phase I trials. The main purpose was to determine feasibility and safety of the intratumoral gene delivery. Patients were treated at different dose-levels. So, the response rate must be established in phase II studies in future. In these studies much more emphasis has been given to elucidate the local effector mechanisms than in the earlier reviewed articles.
Other Inhalation
One phase I study was performed with inhaled IL-2 [92] ( Table 1) . Reversible airway irritation causing a nonproductive cough represented the dose-limiting toxicity. Posttreatment bronchoalveolar lavage showed an activated lymphocyte phenotype with increased HLA-DR expression [92] . Other studies in patients with metastatic renal cell carcinoma with inhaled IL-2 were always done in combination with systemic IL-2 and/or IFN-a s.c. and showed low toxicity [93] [94] [95] . Despite the large number of patients treated, unfortunately no randomised phase III study has been published. Hence, the true value of the locally inhaled IL-2 is still questionable.
Ascites
Intraperitoneal immunotherapy was given for refractory malignant ascites due to metastatic spread of carcinomas of different origin (i.e., gastrointestinal, ovarian, breast, uterus) as palliative treatment. The number of responders (disappearance of ascites) were in all studies high (42%-97%) [75, [96] [97] [98] (Table 1 ). The disappearance of cancer cells, as determined by cytology, was 86% in patients treated with IL-2 and OK-432 [97] . Improvement of performance status and clinical symptoms were observed in responders [97] . After IL-2 and OK-432 administration an increase of cytotoxic activity of CD4+ cells was seen [97] . In responding patients after combination treatment with TNF-a and IFN-y it was shown that an increase of peripheral NK activity occurred [98] .
The standard treatment for patients with ascites is diuretics and/or relieving paracentesis with usually a moderate result. The studies with locoregional therapy showed disappearance of the ascites in the majority of patients. Toxicity was higher than with standard therapy. At this moment it is unclear if it is a good palliative therapy.
Hepatocellular carcinoma or metastases in liver
Intrahepatic immunotherapy can be given by hepatic artery infusion. Both in hepatocellular carcinoma and in case of liver metastases (mostly of colon carcinoma) locoregional immunotherapy as a single treatment is seldom given and there are only case reports published [99] [100] [101] [102] . Locoregional combination immuno-chemotherapy has been given, but because it is combination treatment the relative contribution can only be established in randomised trials. Based on the present anecdotal positive results no conclusions can be drawn [103] [104] [105] . Rat experiments, performed after the earlier mentioned clinical studies, indicate a rationale for IL-2 pre-treatment followed by chemotherapy. In rat it was shown that the hepatic extraction rate of 5-FU was increased after administration of IL-2 [106] .
In conclusion, there is far to less evidence that local immunotherapy is effective in hepatocellular carcinoma or liver metastases. Furthermore, there were no hard data given to use combination treatment of locoregional immuno-and chemotherapy in the above mentioned studies.
Pancreatic carcinoma
No studies have been published where locoregional immunotherapy has been given as single modality. There are studies in irresectable and resectable pancreatic carcinoma in which a combination of immunochemotherapy has been given [107] [108] [109] . However, the rationale for combining these treatments is not well-founded, neither by in vitro investigations, nor by animal experiments. In two randomised studies the patients who have been treated after surgery (curative or palliative surgery) with IL-2 and IFN-y in combination with chemotherapy had an improved survival compared with those who had no additional treatment after surgery [107, 109] . However, it is not clear if the immunotherapy, the chemotherapy or other factors influenced this observation.
Discussion
In this review the clinical studies in which locoregional immunotherapy was administered to patients with cancer were discussed. Most studies used immunotherapy that increased specific or non-specific immune functions or both, i.e., IL-2 or the interferons. Adoptive cell transfer therapy was also used, most in malignant glioma and ovarian carcinoma. The motive for using adoptive cell transfer therapy in malignant gliomas is that the central nervous system is an immunologically privileged site.
After many decades of locoregional immunotherapy, none of the above described therapies has developed to a standard therapy in patients with cancer. Reasons therefore are that in most cancers, except in ovarian carcinoma, the response rates were low. Some of the therapies, i.e., transfer of TIL or LAK cells, are time consuming and very expensive. Although a longer survival in treated patients compared with historical controls was suggested in a number of the reviewed articles, this can only be shown in a prospectively randomised phase III study. Such a study is not performed with any of the above mentioned treatments. Toxicity was always lower than with systemic treatment, but nevertheless present.
The most important reason to give immunotherapy locoregionally is to get a higher concentration of the administered drug in the tumor, to attract or activate the effector cells. However, only in a limited number of the reviewed studies, mainly in HNSCC and in the gene transfer studies, investigations were done to look for the effector mechanism locally and/or systematically. Histological examinations at the site of the tumor have its anatomical limitations, but is essential to get insight in the events triggered in and around the tumor. Repeated cytology might be an alternative. Furthermore, it is known, that immunosuppression at the site of the tumor is present. The tumor has many escape mechanisms to prevent recognition by the immune system, or in case of T-cell activation prevent effective killing [110] . The level and the reversibility of the immune dysfunction before and during immunotherapy are very important [3] . In none of the reviewed studies these tumor related factors are regarded.
It is recommended that in future clinical trials in cancer patients treated with locoregional immunotherapy, both the locoregional immunodysfunction and the effector mechanisms involved will be studied. This will provide a better insight in the reasons of clinical (non)-responsiveness of cancer and lead to a better selection of patients who will benefit from locoregional immunotherapy. Furthermore local investigations may lead to a better insight in the potential of systemic therapy. Studies should be performed in an optimal experimental setting combining both clinical and laboratory expertise.
